Patents by Inventor Piero D. Dalerba

Piero D. Dalerba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10344094
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 9, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
  • Patent number: 9850483
    Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne A. Leyrat, Tomer Kalisky, Maximilian Diehn, Michael Rothenberg, Jianbin Wang, Neethan Lobo
  • Publication number: 20170166645
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Application
    Filed: December 8, 2016
    Publication date: June 15, 2017
    Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
  • Publication number: 20160312302
    Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Inventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne Leyrat, Tomer Kalisky, Maximilian Diehn, Jianbin Wang
  • Patent number: 9329170
    Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: May 3, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne Leyrat, Tomer Kalisky, Maximilian Diehn, Jianbin Wang
  • Publication number: 20130225435
    Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.
    Type: Application
    Filed: July 19, 2011
    Publication date: August 29, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne A. Leyrat, Tomer Kalisky, Maximilian Diehn, Michael Rothenberg, Jianbin Wang, Neethan Lobo
  • Publication number: 20100255471
    Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.
    Type: Application
    Filed: January 20, 2010
    Publication date: October 7, 2010
    Inventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne Leyrat, Tomer Kalisky, Maximilian Diehn